Answers are grounded in this paper and cite their sources.
OBJECTIVE: This study aims to explore whether GBP5 is associated with changing trends in transaminase levels in children with infectious mononucleosis (IM). METHODS: 100 children with IM were divided into the non-liver injury group (NLIG) and the liver injury group (LIG) according to liver function status. The expression level of GBP5 in peripheral blood mononuclear cells (PBMCs) from each group was measured using qPCR. All children with IM underwent liver function reexamination on day 14 after disease onset, leading to a further division into two groups based on these results: the non-progressive transaminase elevation group (NPTEG) and the progressive transaminase elevation group (PTEG). Clinical data and laboratory examination results from all enrolled children were collected for subsequent analysis. RESULTS: Compared with the NLIG, children in the LIG exhibited a higher GBP5 expression level (p < 0.05). Upon reexamination of liver function on day 14 of disease onset, some children showed progressive increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels compared to those at admission. In the PTEG, the expression levels of GBP5 were elevated (p < 0.05). ROC analysis suggested that GBP5 expression showed apparent discriminatory capacity for identifying the risk of progressive transaminase elevation in children with IM. The time to transaminase recovery below 2 × upper limit of normal (ULN) varied among children with IM-related liver injury. >50% achieved recovery within 30 days, with a maximum recovery time of 130 days. CONCLUSION: GBP5 demonstrated apparent predictive discrimination for changing trends in transaminase levels in children with IM, warranting further multivariable assessment and external validation.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: